Cancer treatments are becoming more targeted as we learn more about the molecular biology of different cancer types through advanced research techniques that are able to link specific biomarkers with more targeted individual or combination therapies. These wonderful developments are leading to better outcomes for patients who have previously not responded to traditional cancer therapies. Yet more targeted therapies also pose new challenges, such as insufficient patient populations and clinical trial sizes, the Precision Oncology Forum will provide a platform for collaboration, to find a way towards the continued improvement of patient outcomes.